An expanded access program of Vamorolone for the patients with Duchenne-muscular-dystrophy in Frnace

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Sep 2023 According to a Santhera Pharmaceuticals media release, company has submitted a request for an early access program in France namely an AAP (autorisation dacces precoce), if granted, allow treatment of the first DMD patients with vamorolone in Q4 of this year.
14 Feb 2023 New trial record
08 Feb 2023 According to a Santhera Pharmaceuticals media release, company plans to submit a request in France in the near-term for an early access program for vamorolone for the treatment of Duchenne muscular dystrophy (DMD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com